4th European Biotech & MedTech Investor Day

by France Biotech
ERYTECH’s mission is to leverage red blood cells to improve cancer treatment.

Technology/Products

ERYTECH’s therapeutics are derived from a proprietary technology platform, ERYCAPS, which encapsulates compounds in red blood cells. Our lead program, eryaspase (GRASPA®) encapsulates asparaginase in donor red blood cells. This novel treatment targets solid and liquid tumors acting on “tumor starvation” pathways while increasing the duration of efficacy and significantly reducing the toxicity profile. Eryaspase (GRASPA®) recently announced positive Phase IIb data in metastatic pancreatic cancer (PDAC) and is planning to initiate a global Phase III trial in Q3 2018. The Company is also expecting to initiate a Phase IIb trial in triple negative breast cancer (TNBC) in Q3 2018, and are awaiting CHMP feedback of the MAA resubmission of GRASPA® for R/R ALL in late 2018.

Alliances/Partnerships

The company has licensing and distribution partnership agreements with Orphan Europe (Recordati Group) in Europe, and with TEVA in Israel for the commercialization of GRASPA in ALL and AML.

Upcoming Catalysts

- 2018: Launch of Phase III trial in Pancreatic Cancer
- 2018: Launch of Phase IIb trial in TNBC
- 2018: FDA feedback on U.S. ALL pivotal trial
- 2018: EU CHMP feedback on the MAA for R/r ALL

Market Figures

| Founded          | 2004 |
| Euronext IPO     | 2013 |
| Nasdaq IPO       | Nov 2017 |
| Exchange/Ticker  | Euronext Paris : ERYP  
|                  | Nasdaq Paris: ERYP |
| Currency         | € |
| Market Cap       | €311.3m |
| Price            | €17.66 |
| 52-weeks high    | €29.97 |
| 52-weeks low     | €15.60 |
| Avg.Vol (3mo)    | 27,202 |
COMPANY SUMMARY
BIO Boston 1x1 meeting

ERYTECH

NAME OF THE CEO
Gil BEVEN

ADDRESS
Erytech PharmaSA
60 Avenue Rockefeller
Lyon, France 69008
France

Erytech Pharma Inc.
One Main Street, Suite 1150
Cambridge, Massachusetts 02142, USA

EMAIL
contact@erytech.com
www.erytech.com

TARGETED MARKET
• Oncology
• Rare Diseases
• Immuno-oncology
• Metabolic Disorders

LISTED COMPANY

CREATION DATE
2004

Shareholders

Analyst Coverage

<table>
<thead>
<tr>
<th>Broker</th>
<th>Recommendation</th>
<th>Target Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>Outperform</td>
<td>-</td>
</tr>
<tr>
<td>Gilbert Dupont</td>
<td>Buy</td>
<td>€31.6</td>
</tr>
<tr>
<td>Invest Securities</td>
<td>Buy</td>
<td>€30.0</td>
</tr>
<tr>
<td>JMP</td>
<td>Buy</td>
<td>€50.0</td>
</tr>
<tr>
<td>Jefferies</td>
<td>Buy</td>
<td>€39.0</td>
</tr>
<tr>
<td>Kempen</td>
<td>Buy</td>
<td>€40.0</td>
</tr>
<tr>
<td>Oddo Securities</td>
<td>Buy</td>
<td>€49.0</td>
</tr>
</tbody>
</table>

Pipeline

- Preclinical
- Phase I
- Phase II
- Phase III
- EMA/FDA Review

ALL - EU
ALL - US
PDAC
TNBC
Solid tumors